• # LGM Pharma is a Phenylephrine CAS# 59-42-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Phenylephrine
  • CAS #: 59-42-7
  • Mode of Action:

    In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of the α1-receptor activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on α1-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the α1-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on α1-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities.

  • Pharmacodynamics:

    Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic α1-receptor agonist with little effect on β-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities.

  • Metabolism:

    Undergoes extensive first-pass metabolism in the intestinal wall and extensive metabolism in the liver. Sulfate conjugation, primarily in the intestinal wall, and oxidative metabolism by monoamine oxidase (MAO) represent the principle routes of metabolism. Glucuronidation occurs to a lesser extent. Phenylephrine and its metabolites are mainly excreted in urine/ .

  • IUPAC: Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)- (9CI)
  • PubChem: 6041
  • DrugBank: DB00388
  • Formula: C9-H13-N-O2
  • Molecular Mass: 167.207
  • Synonyms: (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol, Ah-Chew, AI3-02402, Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-, Benzyl alcohol, m-hydroxy-alpha-((methylamino)methyl)-, (-)-, CCRIS 8464, EINECS 200-424-8, Fenilefrina, Fenilefrina [INN-Spanish], HSDB 3383, Isophrin, l-(3-Hydroxyphenyl)-N-methylethanolamine, l-1-(m-Hydroxyphenyl)-2-methylaminoethanol, l-alpha-Hydroxy-beta-methylamino-3-hydroxy-l-ethylbenzene, l-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene, l-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol, m-Methylaminoethanolphenol, m-Oxedrine, m-Sympathol, m-Sympatol, m-Synephrine, Mesaton, Mesatone, Mesatonum, Metaoxedrin, Metaoxedrine, Metaoxedrinum, Metasympatol, Metasynephrine, Mezaton, Neosynephrine, Phenylephrine, Phenylephrine, l-, Phenylephrinum, Phenylephrinum [INN-Latin], R(-)-Phenylephrine, UNII-1WS297W6MV, Visadron
  • SMILES: c1([C@H](CNC)O)cc(ccc1)O
  • AHFS Code:
    • 52:24.00
    • 84:92.00
    • 52:32.00
    • 12:12.04
  • InChl: 1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service